Neuronetics (STIM) Set to Announce Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) will be issuing its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Neuronetics (NASDAQ:STIM) last announced its earnings results on Tuesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.07. The firm had revenue of $20.31 million during the quarter, compared to analyst estimates of $19.73 million. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. During the same quarter in the prior year, the company earned ($0.30) EPS. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Stock Down 2.3 %

Shares of STIM traded down $0.08 during trading hours on Tuesday, hitting $3.46. The company had a trading volume of 6,241 shares, compared to its average volume of 176,408. Neuronetics has a 52-week low of $1.03 and a 52-week high of $5.07. The firm has a fifty day moving average price of $3.93 and a 200-day moving average price of $2.86. The stock has a market capitalization of $103.73 million, a price-to-earnings ratio of -3.30 and a beta of 2.44. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.33 and a current ratio of 4.73.

Analyst Ratings Changes

A number of brokerages recently weighed in on STIM. William Blair restated a “market perform” rating on shares of Neuronetics in a report on Tuesday, March 26th. Piper Sandler reissued an “overweight” rating and issued a $8.00 target price (up previously from $7.00) on shares of Neuronetics in a research report on Wednesday, March 6th.

Insider Buying and Selling at Neuronetics

In related news, CFO Stephen Furlong sold 14,710 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $3.51, for a total value of $51,632.10. Following the transaction, the chief financial officer now owns 509,033 shares of the company’s stock, valued at $1,786,705.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Stephen Furlong sold 14,710 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $3.51, for a total transaction of $51,632.10. Following the completion of the transaction, the chief financial officer now directly owns 509,033 shares in the company, valued at approximately $1,786,705.83. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP William Andrew Macan sold 15,621 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $3.38, for a total transaction of $52,798.98. Following the sale, the executive vice president now owns 417,736 shares in the company, valued at approximately $1,411,947.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 150,279 shares of company stock valued at $489,167. 9.80% of the stock is owned by company insiders.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.